Dimension Therapeutics, Inc. (NASDAQ:DMTX) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.49) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.49), Bloomberg Earnings reports. The firm had revenue of $4.37 million during the quarter. Dimension Therapeutics had a negative net margin of 412.27% and a negative return on equity of 80.04%.
Shares of Dimension Therapeutics (NASDAQ DMTX) remained flat at $1.25 during trading on Wednesday. The company’s stock had a trading volume of 88,437 shares. Dimension Therapeutics has a 12 month low of $1.05 and a 12 month high of $9.98. The company’s market capitalization is $31.30 million. The company’s 50 day moving average is $1.36 and its 200-day moving average is $1.73.
A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Dimension Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Canaccord Genuity decreased their price target on shares of Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, June 28th. Cantor Fitzgerald set a $3.00 price target on shares of Dimension Therapeutics and gave the stock a “hold” rating in a research note on Saturday, June 10th. Finally, Citigroup Inc. downgraded shares of Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $1.50 price objective for the company. in a research report on Friday, May 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Dimension Therapeutics currently has a consensus rating of “Hold” and an average price target of $5.88.
WARNING: “Dimension Therapeutics, Inc. (NASDAQ:DMTX) Announces Earnings Results, Meets Expectations” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://sportsperspectives.com/2017/08/10/dimension-therapeutics-inc-nasdaqdmtx-announces-earnings-results-meets-expectations.html.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.